Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia by Philippe Montravers et al.
REVIEW
Current and Future Considerations for the Treatment
of Hospital-Acquired Pneumonia
Philippe Montravers . Adela Harpan . Elise Guivarch
To view enhanced content go to www.advancesintherapy.com
Received: January 4, 2016 / Published online: February 9, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract: Hospital-acquired pneumonia (HAP)
and health-care-associated pneumonia (HCAP)
are leading causes of death, morbidity, and
resource utilization in hospitalized patients,
and are associated with a broad range of
Gram-positive and Gram-negative pathogens.
Here, we discuss the different definitions of HAP
and HCAP, review current guidelines regarding
the treatment of these conditions, highlight the
shortcomings of current therapeutic options,
and discuss new antibiotic treatments. To
optimize therapeutic outcomes in patients
with HAP/HCAP, initial antimicrobial
treatment must be appropriate and should be
given as soon as possible; inappropriate or
delayed therapy greatly increases morbidity and
mortality. Selection of the most appropriate
antimicrobial agent depends on the causative
pathogen(s); initial broad-spectrum therapy is
commonly recommended and should cover all
pathogens that may be present. Treatment
selection should also take into consideration
the following factors: knowledge of underlying
local risk factors for antimicrobial resistance,
disease staging, and risk factors related to
specific pathogens such as Pseudomonas
aeruginosa, Acinetobacter spp., and methicillin-
resistant Staphylococcus aureus (MRSA).
Guidelines consistently emphasize the
importance of treating HAP and HCAP
with early and appropriate broad-spectrum
antibiotics, and recent developments in this
field have resulted in the availability of several
additional treatment options. Telavancin shows
potent activity against Gram-positive bacteria
including MRSA and can be administered once
daily; it was approved in the USA and European
Union for the treatment of HAP after
demonstrating non-inferiority to vancomycin.
Ceftobiprole medocaril exhibits rapid
antimicrobial activity against a broad range of
both Gram-positive and Gram-negative
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pathogens, including MRSA. It was approved for
the treatment of HAP (excluding ventilator-
associated pneumonia) and community-acquired
pneumonia in Europe in 2013. These new
treatments may offer effective alternative
therapeutic options for the management of HAP.
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INTRODUCTION
Hospital-acquired pneumonia (HAP) is one of
the most common nosocomial infections,
occurring at a rate of 5 to more than 20 cases
per 1000 hospital admissions [1, 2], and is a
leading cause of death, morbidity, and resource
utilization in hospitalized patients [2–6].
Health-care-associated pneumonia (HCAP)
describes pneumonia contracted as a result of
contact with health-care settings other than
hospitals, such as assisted living centers and
rehabilitation facilities. A large, multicenter
study in the USA found that[20% of 4543
patients hospitalized with pneumonia had
HCAP, with mortality similar to that for HAP
(19.8% vs. 18.8%) [7].
This review discusses the different
definitions of HAP and HCAP, reviews current
guidelines regarding the treatment of patients
with these conditions, and highlights the
shortcomings of current therapeutic options.
Antibiotics recently approved for the treatment
of HAP (telavancin and ceftobiprole) together
with tedizolid (currently in clinical
development) are also discussed; new agents
approved for the treatment of ventilator-
associated pneumonia (VAP) are not considered
here as this is beyond the scope of this review.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
DEFINITIONS OF HAP AND HCAP
In the USA and Europe, HAP is defined as
pneumonia that develops 48 h or more after
hospital admission [2, 8, 9]. HAP is distinct from
VAP, which arises more than 48–72 h after
endotracheal intubation [2]. Many patients
with HAP are treated outside the intensive care
unit (ICU) and do not require mechanical
ventilation [10]. HCAP is a more recent term
than HAP and its clinical relevance remains
disputed. HCAP was recognized in the
American Thoracic Society (ATS) 2005
guidelines, which describe a distinct form of
pneumonia not contracted during a hospital
admission, but which resembles HAP more than
community-acquired pneumonia (CAP; see
Table 1 for a full definition of HCAP) [2]. Since
the publication of the ATS guidelines there has
been continued debate about the clinical
relevance of HCAP, and indeed, the term HCAP
may not be retained in the forthcoming updated
ATS guidelines. Joint European guidelines on the
management of HAP, published in 2009 by the
European Respiratory Society (ERS), the
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID), and the European
Society of Intensive Care Medicine (ESICM) call
for HCAP to be recognized as a distinct disease
fromCAP,butdonotprovide a specificdefinition
[11]. However, separate guidelines issued by the
ERS and ESCMID in 2011 on the management of
lower respiratory tract infections (excluding
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HAP) state that ‘‘the evidence base does not
support the use of this term [HCAP] as being
clinically relevant in Europe at the present time’’
[12]; similar doubts were also raised in the
German guidelines published in 2013 [9].
Interestingly, the definition of HCAP used in
clinical studies varies greatly, particularly
regarding the length of time since previous
hospital stay, the definition of and exposure to
health-care facilities, and the inclusion/
exclusion of immunocompromised patients [7,
13, 14]. The heterogeneity of the studies of
patients with HCAP may contribute to the
uncertainty surrounding the acceptance of
HCAP as a distinct subgroup of pneumonia.
RISK FACTORS, ETIOLOGY,
AND DIAGNOSIS OF HAP
AND HCAP
Individuals at the greatest risk of HAP include
elderly people, patients who are
immunocompromised or malnourished,
patients with depression of consciousness,
chronic renal failure, or multiple comorbidities
(e.g., Charlson comorbidity index C3), or those
who have undergone surgery [2, 10]; increased
length of hospital stay is also associated with a
higher risk of developing HAP. Similar risk
factors are documented for HCAP [7, 15].
Etiologies of HAP andHCAP vary according to
geographic area and risk factors. HAP typically
involves infection with a single pathogen, such
as a member of the Enterobacteriaceae (e.g.,
Klebsiella spp., Enterobacter spp., and Serratia
spp.), Staphylococcus aureus (including
methicillin-resistant S. aureus [MRSA]),
Pseudomonas aeruginosa, or Acinetobacter
baumannii [11, 16, 17]. HCAP is typically
associated with pathogens such as Streptococcus
pneumoniae, Klebsiella pneumoniae, and S. aureus
[14, 18, 19].
Questions remain regarding some of the
characteristics of HCAP [20], such as its
association with a high frequency of
multidrug-resistant (MDR) pathogens [21–24]
and the assumption that antibiotic treatment
for CAP would be insufficient for patients with
HCAP [21]. Indeed, several studies have found a
greater prevalence of hard-to-treat or MDR
pathogens in patients with HCAP than in
those with CAP [7, 25, 26]. A study of 4543
patients in the USA found that 18.3% and
16.8% of patients with HCAP and HAP,
respectively, were infected with MRSA,
compared with 6.2% of those with CAP [7].
Furthermore, a study in 727 patients in Spain
reported that penicillin-resistant pneumococcal
strains were more commonly isolated from
patients with HCAP than from those with CAP
(33.3% vs. 14.9%). In contrast, a low incidence
of MDR pathogens was observed in both
patients with HCAP and those with CAP in a
separate study in Spain [22] and in a small UK
study (n = 138) [23].
Rapid identification of the specific causative
pathogen(s) in patients with HAP and HCAP is
essential to ensure that patients receive the most
appropriate treatment as soon as possible. The
identification of specific pathogens is
challenging. The results of bacteriological assays
are not always consistent and reproducible, and
inaccurate cultures can result in failure to treat the
relevant pathogens [2]. Moreover, invasive
techniques for microbiological analysis are often
difficult to performonnonventilated individuals,
and patients may be considered too ill for the
procedure. In addition, specialized laboratories
and training are required for many procedures
and bronchoscopy may not be immediately
available [2, 27].
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TREATMENT OF HAP AND HCAP:
CURRENT GUIDELINES
AND CONSIDERATIONS
The initial approach to the treatment of
patients with HAP and HCAP is often
necessarily empirical because complete results
of antimicrobial susceptibility testing of the
causative pathogens are typically available only
after 48–72 h. Appropriate empirical therapy
should not be delayed, because inadequate and
delayed treatment is associated with increased
morbidity and mortality [28, 29]. Successful
antimicrobial treatment depends on the use of
an agent or regimen that is effective against the
causative pathogen(s), and broad-spectrum
therapy is often recommended [2].
Antimicrobial therapies that act rapidly reduce
the length of hospital stays that in turn reduce
resource utilization and health-care system
costs [28].
US and European Guidelines
A summary of key recommendations from
the major US and European HAP and HCAP
guidelines is provided in Table 1 [2, 8, 9, 11,
30]. In the most recent ATS guidelines (2005)
[2], treatment recommendations for HAP and
HCAP are based on whether or not patients
have risk factors for MDR pathogens, with
more aggressive therapeutic strategies
recommended for those who do; notably, all
patients with HCAP are classified as being at
risk of having MDR pathogens. Approaches to
initial therapy provided in individual
guidelines from Europe range from disease
stage-specific antibiotic interventions to
decision-making based on local conditions;
however, as with the ATS recommendations,
most guidelines categorize treatment
strategies according to the risk of the
presence of MDR bacteria [2, 30, 31]. Where
this approach is employed, aminopenicillins
with b-lactamase inhibitors, second- or
third-generation cephalosporins, quinolones,
or ertapenem are advocated for patients
considered to be at low risk (e.g.,
early-onset HAP and/or no MDR pathogen
risk). For patients thought to be at higher risk
(e.g., late-onset HAP, MDR pathogen risk, in
the ICU, and/or with organ failure), imipenem,
meropenem, fourth-generation cephalosporins,
ceftazidime, or piperacillin/tazobactam
plus quinolones or aminoglycosides are
recommended, depending on the degree of
risk [32]. When MRSA is implicated in HAP, all
guidelines recommend either linezolid or
vancomycin (Table 1), but do not state a
preference because direct comparisons have
shown no difference in overall survival rate
(although cure rates are higher with linezolid)
[33]. It should also be emphasized that the
therapeutic response is often poor if P.
aeruginosa and MRSA are present, and
infections with either of these pathogens are
difficult to treat even when appropriate initial
antibiotic therapy is used [34–36].
Joint European guidelines for the
management of HAP recommend that
treatment is selected according to the timing of
disease onset (early onset [B4 days of hospital
admission] or late onset [ 4 days of hospital
admission]) and whether risk factors are present
(any onset) (Table 1) [11]. Where risk factors are
present, the choice of therapy should reflect the
suspected pathogen and take local bacterial
spectrums into consideration. Once the
pathogen responsible has been identified,
therapy should focus on the relevant
pathogen(s), and most patients should be
switched to monotherapy after 3–5 days [11].
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National and Local Guidelines
Treatment guidelines at the national level vary
from general considerations and broad therapy
suggestions to specific recommendations for
different patient types and pathogens. Recent
national guidelines highlight the importance of
considering the spectrum of pathogens in the
local area and their resistance profiles. The 2013
German guidelines categorize treatments for
HAP based on whether or not patients have
risk factors for the presence of MDR pathogens
(Table 1) [9]. The guidelines advocate continuing
treatment for 8 days, with de-escalation 48–72 h
after the start of treatment when appropriate [9].
In contrast to these specific recommendations,
UK guidelines for the management of HAP
published in 2008 contain few definitive
treatment recommendations (Table 1), citing
lack of conclusive clinical evidence [30]. In
December 2014, the UK National Institute for
Health and Care Excellence (NICE) issued
updated guidance beyond areas of care for
which best practice was already established,
recommending (i) the prompt initiation of
therapy (certainly within 4 h), (ii) that the
choice of therapy should reflect local hospital
policy, and (iii) that a 5- to 10-day course of
therapy be considered (Table 1) [8].
Further and more detailed guidelines for the
treatment of HAP are often issued at regional or
local levels and even by individual hospitals [37,
38], although few of these are readily available.
Recommendations at the local level tend to
reflect differences in the spectrum of pathogens
associated with HAP in the particular area. An
example of this is the guidance related to MRSA,
which has a higher prevalence in southern
Europe than in northern Europe [39],
potentially linked to increased antibiotic use
in southern Europe [40]. Treatment strategies
may also be tailored to local resistance patterns.
For example, policies issued by the Royal Devon
and Exeter NHS Foundation Trust (south-west
UK) recommend vancomycin for all patients
with moderate-to-severe HAP who are at high
risk of MRSA infection [37], while those from
Nottingham University Hospitals NHS Trust
(central UK) note that nearly all S. aureus
strains are sensitive to gentamicin and
doxycycline, so linezolid and vancomycin are
recommended only for patients in the ICU
where there is known MRSA colonization [38].
Further Considerations for Treatment
Selection
Guidelines are important for providing
recommendations on which treatments (or
classes of treatments) are appropriate for HAP/
HCAP, but patient-specific considerations also
influence treatment choice. These include
duration of hospitalization before development
of pneumonia, HAP staging, antimicrobial
resistance patterns within the hospital, and
previous antibiotic use [29]. Patient risk factors
such as older age, presence of congestive heart
failure, corticosteroid treatment, endotracheal
intubation, neutropenia, and septic shock also
affect the choice of therapy [28]. In addition,
many patients with HAP or HCAP have
comorbidities such as chronic renal failure that
exclude them from receiving certain treatments
[7, 41].
Therapeutic Failure and De-escalation
of Therapy
Failure to respond to initial empirical antibiotic
therapy can be expected in approximately
20–40% of patients with HAP, depending on
the causative pathogen, the nature of the
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infection, and the presence and severity of
comorbidities [11]. Therapeutic failure requires
immediate and extensive diagnostic
re-evaluation of the patient, including
bronchoscopic respiratory secretion sampling
and blood cultures [11, 42]. This should be
accompanied by assessment of other
complications, alternative diagnoses (e.g.,
atelectasis, congestive heart failure), and other
sites of infection in the patient [2].
Effective de-escalation of broad-spectrum
empirical therapy is important if patients’
exposure to antibiotics and treatment resistance
are to be minimized. The current European
guidelines recommend that de-escalation begins
once the pathogen has been identified (usually
after3–5 days; after2–3 days inGermany) (Table 1)
[9, 11]. De-escalation can be conducted in several
ways. First, therapy can focus on an antibioticwith
a narrower spectrum of activity. In particular,
vancomycin and linezolid treatment should be
stopped if MRSA is not identified, and very
broad-spectrum agents, such as carbapenems,
piperacillin–tazobactam, and/or cefepime, should
be restricted to patients infected with pathogens
susceptible only to these agents [11]. Secondly, if
the dosage of the initial antibiotic was high (e.g.,
based on pharmacodynamic optimization), it can
be reduced to a standard dosage for a susceptible
organism. Thirdly, if no pathogen is identified but
clinical improvement has been observed,
antibiotic therapy can be reduced (usually, to
b-lactam monotherapy) or discontinued
altogether [9, 11].
NEW TREATMENT OPTIONS
FOR HAP AND HCAP
The persisting high mortality associated with
HAP and HCAP [5, 7] indicates that current
treatments are far from optimal. In addition to
suboptimal efficacy, factors such as high
nephrotoxicity rates (in 15.4% of patients with
HAP treated with vancomycin) [43] and
myelosuppression (associated with linezolid)
[44] limit the use of certain antimicrobials. In
addition, infections involving MRSA, mixed
Gram-positive and Gram-negative bacteria, or
MDR pathogens cannot currently be treated
adequately by any single agent [5]. Hence, there
remains a need for additional antibiotics that
provide well-tolerated, broad-spectrum activity
against MDR pathogens. Furthermore,
alternative broad-spectrum antibiotics for HAP
may offer carbapenem-sparing treatment
options and thus help reduce the resistance
selection pressure on carbapenems and limit the
emergence of carbapenemases. The availability
of such treatments would simplify the initial
empirical therapy for HAP and HCAP.
In the ‘golden age’ of antibiotic development
between 1935 and 1968, 14 classes of drug were
introduced for human use. Since then, only five
new classes have been added. Few new
therapeutic agents for HAP have been
approved recently. The most promising recent
approvals include telavancin and ceftobiprole
medocaril (Table 2) [45, 46]; tedizolid
phosphate is currently being investigated for
the treatment of CAP, HAP, VAP, and
bacteremia.
Telavancin
Telavancin is a semisynthetic lipopolypeptide
with approximately tenfold greater potency
than vancomycin [47] and exclusively displays
in vitro activity against clinically important
Gram-positive bacteria including MRSA,
vancomycin-intermediate S. aureus, and
penicillin-resistant S. pneumoniae [47–50].
Bactericidal activity is concentration
dependent and, with a half-life of 7–9 h,
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telavancin is suitable for once-daily dosing [51,
52]. On the basis of the results of the
Assessment of Telavancin for Treatment of
Hospital-Acquired Pneumonia (ATTAIN)
studies, telavancin was approved in Europe
(2011) and the USA (2013) for the treatment
of HAP caused by Gram-positive pathogens
including MRSA when alternative therapies are
not suitable (Table 2) [45]. The two ATTAIN
studies (ClinicalTrials.gov identifiers,
NCT00107952 and NCT00124020) were
double-blind, phase 3 clinical trials that
assessed the efficacy and safety of telavancin
in a total of 1503 patients with HAP caused by
Gram-positive pathogens [53]. In the pooled
all-treated population, intravenous (i.v.)
telavancin 10 mg/kg every 24 h (n = 749) was
non-inferior to vancomycin 1 g i.v. every 12 h
(n = 754) in terms of clinical cure rate at the
follow-up/test-of-cure (TOC) visit [58.9% vs.
59.5%, respectively; 95% confidence interval
(CI) for the difference -5.6%, 4.3%]. Moreover,
in the subgroup of patients with S. aureus
infection (n = 433), telavancin provided a
higher clinical cure rate at the TOC visit than
vancomycin (78.1% vs. 75.2%; 95% CI for the
difference -5.0%, 11.0%). Cure rates were
similar in the subgroup of patients with MRSA
infection (n = 293; 74.8% and 74.7% for
telavancin and vancomycin, respectively; 95%
CI for the difference -9.5%, 10.4%).
A post hoc analysis reported similar 28-day
survival rates with telavancin and vancomycin
(76% and 77%, respectively) [55], consistent
with the mortality data from the original
analyses [53]. However, lower survival rates
were observed with telavancin compared with
vancomycin (59% vs. 70%) in patients with
moderate-to-severe renal insufficiency
(creatinine clearance \50 mL/min) [54, 55];
consequently, a black box warning for patients
with inadequate renal function was added to
the label in the USA. A subsequent post hoc
analysis of the ATTAIN studies has suggested
that the higher mortality rate for telavancin
compared with vancomycin (telavancin,
179/751 patients; vancomycin, 163/752
patients) may have been confounded by
inadequate coverage of Gram-negative
infections, especially in the telavancin group
[54]. Indeed, there were more patients with
Gram-negative only infections and with
inadequate treatment of those infections in
the telavancin group than the vancomycin
group. However, consistent with the black box
warning, the post hoc analysis also found
increased mortality with telavancin compared
with vancomycin in patients with poor renal
function (telavancin, 20/32 patients;
vancomycin, 7/27 patients [creatinine
clearance\30 mL/min]) [54].
Rates of treatment-emergent adverse events
(AEs) were the same for telavancin and
vancomycin (both 82%); the most common AEs
were diarrhea, anemia, hypokalemia,
constipation, and renal impairment. The
proportion of patients experiencing serious AEs
was higher in the telavancin group than in the
vancomycin group (31% vs. 26%). AEs leading to
study discontinuation were also higher with
telavancin than with vancomycin (8% vs. 5%);
acute renal failure was the most common AE
associatedwith discontinuation in the telavancin
group (1.2%) [53]. AEs associated with telavancin
included transient elevations in serum creatinine
levels, thrombocytopenia and QT prolongation,
although to date no cardiovascular events
attributed to QT prolongation have been
reported [53, 56–58]. It is recommended that
patients receiving telavancin are monitored
closely (particularly, their renal function), owing
to the associated AEs [45].
The potent activity of telavancin against
Gram-positive HAP pathogens (including
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MRSA, vancomycin-intermediate S. aureus, and
penicillin-resistant S. pneumoniae), and the
convenient, once-daily dosing regimen may
offer advantages over conventional therapies
(Table 2). However, telavancin is not effective
against Gram-negative bacteria [59]. In
addition, it is not indicated for patients with
severe renal impairment and the risk of
nephrotoxicity necessitates constant
monitoring of renal function [45].
Ceftobiprole Medocaril
Ceftobiprole medocaril, the prodrug of the
active moiety ceftobiprole, is a new-generation,
broad-spectrum i.v. cephalosporin. Ceftobiprole
has unique activity against MRSA and a broad
range of Gram-positive and Gram-negative
pathogens [60], with high activity against
methicillin-susceptible S. aureus, MRSA and
S. pneumoniae (100%, 98.3%, and 99.3%
susceptibility, respectively) [61]. Interestingly,
ceftobiprole appears to have high affinity for
most penicillin-binding proteins (PBPs); in
Escherichia coli, the major targets seem to be
PBP1b and PBP2 rather than PBP3 (the target for
third-generation cephalosporins) [62]. This PBP
binding contributes to the potent activity of
ceftobiprole against most Enterobacteriaceae spp.
(87.3% susceptibility); the activity of
ceftobiprole against P. aeruginosa is similar to
that of ceftazidime (64.6% susceptibility) [61].
The efficacy of ceftobiprole in patients with
HAP was assessed in a double-blind,
randomized, controlled phase 3 study
(n = 781, intent-to-treat [ITT] population,
including 210 patients with VAP) with a
dosing regimen of 500 mg i.v. every 8 h
(ClinicalTrials.gov identifiers: NCT00210964
and NCT00229008) [63]. Ceftobiprole was
non-inferior to ceftazidime for clinical cure
(2 g i.v. every 8 h, plus linezolid 600 mg i.v.
twice daily) for both the whole population (ITT;
49.9% vs. 52.8%, respectively) and the
HAP-specific patient subgroup (n = 571; 59.6%
vs. 58.8%, respectively), although not in
patients with VAP (23.1% vs. 36.8%,
respectively) [63]. This difference in clinical
cure rates was also evident when
microbiologically evaluable (n = 332) patients
were stratified according to baseline pathogen
profile [63]. The microbiological eradication
rates in patients with HAP (excluding VAP)
were 62.9% vs. 67.5% in the ceftobiprole and
ceftazidime plus linezolid groups, respectively;
in patients with VAP, the microbiological
eradication rates were 30.4% vs. 50.0%,
respectively. Overall, 30-day all-cause mortality
and 30-day pneumonia-specific mortality were
similar in the ceftobiprole and
ceftazidime/linezolid treatment groups. Similar
rates of treatment-related AEs were reported for
ceftobiprole (24.9%) and ceftazidime/linezolid
(25.4%) [63, 64]. Furthermore, in a randomized
controlled trial in 638 patients requiring
hospitalization for CAP (ClinicalTrials.gov
identifier: NCT00326287), ceftobiprole 500 mg
i.v. twice daily was shown to be non-inferior to
ceftriaxone 2 g i.v. once daily (with or without
linezolid 600 mg i.v. twice daily) for clinical
cure [65].
Regulatory approval for ceftobiprole was
obtained in October 2013 for the treatment of
CAP and HAP, but not VAP, in 13 European
countries (Table 2) [46, 66]. Ceftobiprole is also
approved in Canada. At present, it is not
approved in the USA (Table 2). The Food and
Drugs Administration (FDA) raised some Good
Clinical Practice concerns in 2008 over a
number of ceftobiprole studies, but this was
with regard to studies in complicated skin
infections and did not affect those for
pneumonia (HAP or CAP). Importantly,
following inspections of the pneumonia
Adv Ther (2016) 33:151–166 161
clinical trial sites conducted by regulatory
agencies during the European regulatory
review, it was concluded that the data from
these studies were reliable and represent a fair
assessment of the efficacy and safety of
ceftobiprole in these indications. Moreover, in
August 2015, the FDA designated ceftobiprole as
a Qualified Infectious Disease Product with
potential use in the treatment of CAP and
acute bacterial skin and skin structure
infections.
The standard dose of ceftobiprole is 500 mg
every 8 h; dose adjustment of ceftobiprole is
recommended in patients with moderate or
severe renal impairment [46]. In individuals
with moderate impairment (CLCR 30 to\50 mL/
min), the recommended dose is 500 mg
administered as a 2-h i.v. infusion every 12 h;
for those with severe impairment
(CLCR\30 mL/min) the recommended dose is
250 mg administered as a 2-h i.v. infusion every
12 h, and for patients with end-stage renal
disease the recommended dose is 250 mg once
every 24 h [46]. There is no need for dose
adjustment based on sex, ethnicity, age, or
hepatic impairment [46].
Tedizolid
Tedizolid is a novel oxazolidinone antibiotic
with potent activity against a wide range of
Gram-positive pathogens, including MRSA
and vancomycin-resistant enterococci (MIC90
0.25–0.5 lg/mL) [67]. A phase 3, randomized,
double-blind study comparing the efficacy
and safety of tedizolid and linezolid is
ongoing in patients with HAP and VAP, and
is expected to be complete in February 2018
(ClinicalTrials.gov identifier: NCT02019420).
CONCLUSION
Both HAP and HCAP are common infections
associated with high mortality and resource
utilization. HCAP is not consistently
recognized, but may be associated with an
etiology more closely related to HAP than
CAP. It is important to treat HAP and HCAP
early with broad-spectrum antibiotics, because
inadequate empirical therapy is associated with
increased mortality and health-care costs. The
current treatments for HAP and HCAP include
all broad-spectrum antibiotics, but the burden
of HAP and HCAP remains high. Additional
treatment options have recently become
available. Telavancin exhibits potent
antibacterial activity against a range of
Gram-positive bacteria, including MRSA, and
has demonstrated non-inferiority to
vancomycin in patients with HAP. The
new-generation cephalosporin ceftobiprole
shows rapid and potent antibacterial activity
against a broad range of both Gram-positive
(including MRSA) and Gram-negative
pathogens important in HAP. It has
demonstrated non-inferiority to combination
therapy with ceftazidime and linezolid in
patients with HAP (excluding VAP). These new
agents may offer effective alternative options
for the management of HAP.
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